Study of GLPG1837 in Subjects With Cystic Fibrosis (G551D Mutation)

NCT02707562 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

26

Enrollment

INDUSTRY

Sponsor class

Conditions

Cystic Fibrosis

Interventions

DRUG: GLPG1837 dose 1
DRUG: GLPG1837 dose 2
DRUG: GLPG1837 dose 3

Sponsor

Lakefront Biotherapeutics NV